Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible (Q48004295)

7 February 2018

title

Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible (English)

1 reference

7 February 2018

author

Leo Visser

5

1 reference

7 February 2018

Guus Rimmelzwaan

7

object named as

G F Rimmelzwaan

1 reference

7 February 2018

author name string

L B S Gelinck

1

1 reference

7 February 2018

B J F van den Bemt

2

1 reference

7 February 2018

W A F Marijt

3

1 reference

7 February 2018

A E van der Bijl

4

1 reference

7 February 2018

H A Cats

6

1 reference

7 February 2018

F P Kroon

8

1 reference

7 February 2018

language of work or name

English

0 references

publication date

24 February 2009

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

27

1 reference

7 February 2018

issue

18

1 reference

7 February 2018

page(s)

2469-2474

1 reference

7 February 2018

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Immunization of transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Recent advances in vaccine adjuvants for systemic and mucosal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Mass vaccination: solutions in the skin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Anatomical mapping of epidermal Langerhans cell densities in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Influenza vaccine dosages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Immunization with influenza virus A vaccines. Comparison of intradermal and subcutaneous routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Immunization with Asian-strain influenza vaccine: equivalence of the subcutaneous and intradermal routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Serum antibody responses after intradermal vaccination against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Dose sparing with intradermal injection of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Intradermal influenza vaccination--can less be more?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Reduced-dose influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Antibody responses after dose-sparing intradermal influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Letter: Intradermal influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Weathering the influenza vaccine crisis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

The macro-epidemiology of influenza vaccination in 56 countries, 1997--2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Influenza immunisation: attitudes and beliefs of UK healthcare workers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Intradermal vaccination against influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

The fate of human Langerhans cells in hematopoietic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

Immunogenicity and Safety of an Intradermal Boosting Strategy for Vaccination Against Influenza in Lung Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.053

10.1016/J.VACCINE.2009.02.053

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

release_dr6j7voqovas7ims2t5uxtijwe

Fatcat ID

0 references

1 reference

7 February 2018